Tyra Biosciences, Inc. (TYRA) Stock
TYRA has an Alpha Score of 27 out of 100 (poor), computed on Nov 3, 2026 from 2 of 4 sub-scores. 4 of the hedge funds AlphaScala tracks reported TYRA in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Marshall Wace's at $18.63M. Company insiders reported 1 open-market buy and 0 sales on SEC Form 4 in the 90 days to Nov 10, 2026.
What is TYRA's Alpha Score?
How it works →Alpha Score of 27 reflects poor overall profile with poor momentum, moderate quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 3, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own TYRA?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Marshall Wace | 583K | $18.63M | +195% |
| Citadel Ken Griffin | 278K | $8.89M | +1708% |
| Millennium Management Israel Englander | 178K | $5.67M | -20% |
| D.E. Shaw David Shaw | 20K | $644.8K | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Tyra Biosciences, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 9, 26 | Verjee Rehan | Director | BUY | 971.894 | $20K |
SEC Form 4 filings as of Nov 10, 2026
See cluster-buy signals across all tickers →What are TYRA's key statistics?
Key statistics as of Nov 11, 2026
TYRA price chart
Powered by TradingViewWhat does Tyra Biosciences, Inc. do?
Tyra Biosciences Inc. is a biotechnology company focused on developing precision therapies to address drug resistance in cancer treatments. Founded with the mission to advance cancer therapy through targeted innovation, Tyra Biosciences specializes in creating small-molecule inhibitors that can overcome the limitations of current treatments. The company's research and development efforts concentrate on specific gene alterations that drive drug resistance, thereby crafting solutions with the potential to improve patient outcomes. Tyra Biosciences plays a pivotal role in the healthcare sector, particularly in the field of oncology, where the demand for more effective and personalized treatment options is growing. The company leverages cutting-edge technology and deep molecular understanding, aiming to then translate these scientific insights into viable clinical products. While its innovations are currently most impactful within oncology, the methodologies and discoveries could extend to other diseases characterized by resistance mechanisms. Being a part of the competitive biotechnology market, Tyra Biosciences contributes to the ongoing development of novel therapeutics that aim to meet unmet medical needs, thus enhancing its significance in the efforts toward more robust cancer treatment solutions.